Company intelligence / Profile preview

Tanox, Inc.

Houston, Texas, United Statestanoxltx.com ↗

Ownership: Private
Development stage: Commercial

Overview

Tanox's first approved drug was Xolair (omalizumab), the first anti-IgE antibody brought to market. Xolair achieved $320 million in U.S. sales in 2005. The company also had TNX-355, a viral-entry inhibitor antibody for HIV/AIDS that showed significant antiviral activity in Phase 2 clinical testing.

Therapeutic areas: PulmonologyOphthalmologyImmunologyEndocrinologyOncologyInfectious Diseases
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

4 assets

omalizumab

Commercial

Indications: Allergic asthma, Seasonal allergic rhinitis

3 more assets in the full pipeline.

Request access →

Partnerships

Genentech, Inc.Novartis Pharma AG (formerly Ciba-Geigy Ltd.)

Beyond the preview

Go deeper on Tanox, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tanox, Inc..

Explore the full profile